Amerimmune Pharmaceuticals Announces Appointment of New Director.LOS ANGELES--(BW HealthWire)--Sept. 30, l999-- Amerimmune Pharmaceuticals, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:AMUN) today announced that Rex H. Lewis has joined the Company's Board of Directors. Lewis, a private investor, replaces Lois Rezler, who has resigned. Amerimmune Pharmaceuticals, Inc. is engaged in pharmaceutical research and development with the primary purpose of developing Cytolin(R), a drug designed to protect the immune system, especially in patients suffering from Human Immunodeficiency Virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. (HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. ). The company believes that Cytolin is an important drug for the growing number of patients who have not been receiving treatment, for those who are on multi-drug therapy, and for those who have become resistant to drugs currently used to treat the HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome virus. For more information, visit the company's Web site, www.amerimmune.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion